Dr. Tucker’s company is developing pioneering molecular-targeted therapies for the world’s deadliest blood clotting diseases including stroke and heart attack. He also is a part-time faculty member in the department of biomedical engineering at OHSU.
His academic research is focused on molecular nature of blood coagulation and its role in helping develop new and safer antithrombotic treatments. He has authored 27 scientific articles, and received several recognitions including the Young Investigator Award from the International Society on Thrombosis & Haemostasis and a T32 National Research Service Award from the National Institutes of Health.
Dr. Tucker has directed nine Small Business Innovation Research (SBIR) grants as principal investigator, and regularly serves as a reviewer for NIH SBIR/STTR grant applications. He also helped negotiate a strategic alliance with Bayer Healthcare.
His achievements were recognized in 2015 when he was selected as a member of the Portland Business Journal’s “40 under 40” class. His educational credentials include a BS degree from University of Oregon and a PhD in biomedical engineering from OHSU.
“I can assist in areas of business creation, formation of a good accounting infrastructure to support Federal grants and general management and leadership. In addition, I can advise on negotiating partner agreements, licensing technology from academic institutions, preparing for A-133 audits and all aspects of SBIR/STTR grants. I also can consult on biologic drug development in the preclinical stage.”